Insider Transactions in Q3 2021 at Immuneering Corp (IMRX)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
4,750
+48.23%
|
$114,000
$24.45 P/Share
|
|
Sep 13
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
349
+50.0%
|
$7,329
$21.25 P/Share
|
|
Sep 13
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Indirect |
5,750
+1.44%
|
$120,750
$21.51 P/Share
|
|
Sep 13
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,083
+0.08%
|
$45,826
$22.87 P/Share
|
|
Aug 03
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
550,000
+19.62%
|
$8,250,000
$15.0 P/Share
|
|
Aug 03
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,702,628
+50.0%
|
-
|
|
Aug 03
2021
|
Biren Amin CFO, TREASURER |
BUY
Open market or private purchase
|
Direct |
4,175
+37.7%
|
$62,625
$15.0 P/Share
|
|
Aug 03
2021
|
Biren Amin CFO, TREASURER |
BUY
Conversion of derivative security
|
Direct |
2,723
+50.0%
|
-
|
|
Aug 03
2021
|
Scott Barrett CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
667
+9.1%
|
$10,005
$15.0 P/Share
|
|
Aug 03
2021
|
Scott Barrett CHIEF MEDICAL OFFICER |
BUY
Conversion of derivative security
|
Direct |
5,996
+50.0%
|
-
|
|
Aug 03
2021
|
Ann E Berman Director |
BUY
Open market or private purchase
|
Direct |
3,500
+50.0%
|
$52,500
$15.0 P/Share
|
|
Aug 03
2021
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Open market or private purchase
|
Direct |
1,402
+50.0%
|
$21,030
$15.0 P/Share
|
|
Aug 03
2021
|
Robert J Carpenter Director |
BUY
Open market or private purchase
|
Direct |
325,000
+22.05%
|
$4,875,000
$15.0 P/Share
|
|
Aug 03
2021
|
Robert J Carpenter Director |
BUY
Conversion of derivative security
|
Direct |
217,173
+20.86%
|
-
|
|
Aug 03
2021
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
1,353
+17.47%
|
$20,295
$15.0 P/Share
|
|
Aug 03
2021
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Conversion of derivative security
|
Direct |
5,040
+50.0%
|
-
|
|
Aug 03
2021
|
Laurie Keating Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$105,000
$15.0 P/Share
|
|
Aug 03
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,098
+0.08%
|
$31,470
$15.0 P/Share
|
|
Aug 03
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
49,099
+1.85%
|
-
|
|
Aug 03
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Indirect |
291,667
+22.93%
|
$4,375,005
$15.0 P/Share
|
|
Aug 03
2021
|
Peter Feinberg Director |
BUY
Conversion of derivative security
|
Indirect |
338,835
+36.78%
|
-
|